Cipla Ltd. — Regulatory Filings 2021

Mar 31, 2021

==> picture [116 x 47] intentionally omitted <==

31[st] March, 2021

(1) BSE Ltd (2) National Stock Exchange of India Ltd Listing Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th] floor, Dalal Street, Plot no. C/1, G Block, Mumbai - 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub: Agreement to contribution in ABCD Technologies LLP

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that Cipla Limited has entered into an agreement to become a partner in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP).

The details required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure – A.

Kindly acknowledge receipt.

Thanking you,

Yours faithfully,

For Cipla Limited

Digitally signed by RAJENDRA CHOPRA RAJENDR DN: c=IN, o=Personal, 2.5.4.20=4987ad48c3965cfde78c8ea6 9e6f40ac91535876f12ba1fa5ba45cc5 cc8db6cb, postalCode=122001, A st=HARYANA, serialNumber=0be85c0408d0e3afd66 3669f5314248a72fdcdf34d01d48d47 CHOPRA 2d7cf9262696f6, cn=RAJENDRA CHOPRA Date: 2021.03.31 13:08:19 +05'30' Rajendra Chopra Company Secretary

Encls: 1. Details as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

==> picture [469 x 40] intentionally omitted <==

==> picture [116 x 47] intentionally omitted <==

Annexure A

a) Name of the target entity, details in brief such as size, turnover etc.:	i) Name of the Target entity:ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) (hereinafter referred to as Target entity). ii) Details of Target entity: The Target entity is a recently incorporated limited liability partnership (“LLP”) and is yet to commence business activities.
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms-length”;	The transaction does not fall within the purview of related party transaction. None of the promoter/promoter group/group companies have any interest in the entity.
c) Industry to which the entity being acquired belongs;	Digital Supply Chain~~-H~~ealthcare/Pharmaceutical and allied segments. services
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The transaction is in line with Company’s strategy on leveraging digital assets and philosophy of access and affordability of medicine to all. The proposed business of Target entity will be carried out with an objective to facilitate the digitization of the healthcare infrastructure in India towards enhancement of Good Distribution Practices (“GDP”) inter alia, in support of the National Digital Health Mission of Government of India (“Business.”).
e) Brief details of any governmental or regulatory approvals required for the acquisition;	None.
f) Indicative time period for completion of the acquisition;	31stMarch, 2021 Subsequent tranches of contribution will follow basis the contribution made by other partners.
g) Nature of consideration-whether cash consideration or share swap and details of the same;	Cash infusion as capital contribution towards partnership.
h) Cost of acquisition or the price at which the shares are acquired;	Contribution upto INR 40 crores corresponding to the contribution by the other partners. The overall contribution is scalable over a period of time with the same share of profit/loss corresponding to the contribution of other partners.

==> picture [469 x 40] intentionally omitted <==

==> picture [116 x 47] intentionally omitted <==

i) Percentage of shareholding / control acquired and/or number of shares acquired;

Upto 20% share of profit/ loss in LLP.

j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);

The Target entity was incorporated on 10th February, 2021 with an object to facilitate, enable and promote efficiency in pharma supply chain and larger pharma ecosystem to enable the stakeholders to provide better and more affordable patient care solutions, in line with the objectives of NDHM with activities strictly in compliance with applicable law. The LLP will be an industry digital initiative by certain major pharmaceutical companies. The Target entity will be a holding entity and would undertake busines through one more LLPs or subsidiaries.

Digitally signed by RAJENDRA CHOPRA DN: c=IN, o=Personal, 2.5.4.20=4987ad48c3965cfde78c8ea69e RAJENDR 6f40ac91535876f12ba1fa5ba45cc5cc8d b6cb, postalCode=122001, st=HARYANA, serialNumber=0be85c0408d0e3afd663 A CHOPRA 669f5314248a72fdcdf34d01d48d472d7 cf9262696f6, cn=RAJENDRA CHOPRA Date: 2021.03.31 13:08:39 +05'30'

==> picture [469 x 40] intentionally omitted <==